• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Estimating SARS-CoV-2 infection probabilities with serological data and a Bayesian mixture model

tetano

Editor, Senior Moderator
Sci Rep


. 2024 Apr 25;14(1):9503.
doi: 10.1038/s41598-024-60060-3. Estimating SARS-CoV-2 infection probabilities with serological data and a Bayesian mixture model

Benjamin Glemain[SUP] 1 2 [/SUP], Xavier de Lamballerie[SUP] 3 [/SUP], Marie Zins[SUP] 4 5 [/SUP], Gianluca Severi[SUP] 6 7 [/SUP], Mathilde Touvier[SUP] 8 [/SUP], Jean-François Deleuze[SUP] 9 [/SUP]; SAPRIS-SERO study group; Nathanaël Lapidus[SUP] #[/SUP][SUP] 10 11 [/SUP], Fabrice Carrat[SUP] #[/SUP][SUP] 10 11 [/SUP]



Collaborators, Affiliations
Abstract

The individual results of SARS-CoV-2 serological tests measured after the first pandemic wave of 2020 cannot be directly interpreted as a probability of having been infected. Plus, these results are usually returned as a binary or ternary variable, relying on predefined cut-offs. We propose a Bayesian mixture model to estimate individual infection probabilities, based on 81,797 continuous anti-spike IgG tests from Euroimmun collected in France after the first wave. This approach used serological results as a continuous variable, and was therefore not based on diagnostic cut-offs. Cumulative incidence, which is necessary to compute infection probabilities, was estimated according to age and administrative region. In France, we found that a "negative" or a "positive" test, as classified by the manufacturer, could correspond to a probability of infection as high as 61.8% or as low as 67.7%, respectively. "Indeterminate" tests encompassed probabilities of infection ranging from 10.8 to 96.6%. Our model estimated tailored individual probabilities of SARS-CoV-2 infection based on age, region, and serological result. It can be applied in other contexts, if estimates of cumulative incidence are available.

Keywords: Bayes’ theorem; COVID-19; Mixture model; SARS-CoV-2.

 
Back
Top Bottom